Heron Therapeutics | HRTX - Stock


Heron Therapeutics reported $54.57M in Stock for its fiscal quarter ending in December of 2022.





Stock Change Date
ALKERMES USD 336.7M 140.08M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amarin USD 183.58M 12.32M Mar/2026
ANI Pharmaceuticals USD 143.47M 401K Mar/2026
Anika Therapeutics USD 22.84M 4.05M Mar/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
Eisai JPY 236.46B 9.14B Sep/2025
Emergent BioSolutions USD 328.9M 25.2M Dec/2023
Esperion Therapeutics USD 104.21M 915K Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Insmed USD 132.91M 841K Mar/2026
Ligand Pharmaceuticals USD 13.27M 4.14M Mar/2026
Merck USD 6.48B 179M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Omeros USD 712K 266K Sep/2021
Pacira USD 150.37M 2.49M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Veracyte USD 21.42M 870K Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026